Migraines in youths with low Vitamin D wonderfully treated by Vitamin D

Evaluation of Vitamin D Levels and Response to Therapy of Childhood Migraine.

Medicina (Kaunas). 2019 Jun 28;55(7). pii: E321. doi: 10.3390/medicina55070321.

Kılıç B1, Kılıç M2.

  • 1 Dept of Child Neurology, University of Health Sciences, Derince Training and Research Hospital, 41900 Kocaeli, Turkey. betulklc82@gmail.com.

  • 2 Dept of Neurosurgery, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, 34371 Istanbul, Turkey. kilicnrs@gmail.com.

6 month trial on migraine youths of average age 13 who had < 20ng level of vitamin D Started with 2,000 IU for 2 months, then 600 to 1,000 IU daily for 4 months Expect that they would have had even better success by Using larger dose sizes so as to get most of them >30 ng    - Larger doses especially for those who were heavier/overweight Adding Magnesium and Zinc Also expect that the Migraines would have been reduced in a few weeks if they had used a loading dose of Vitamin D Note: Both Migraines and Cluster headaches in adults have been very succesfully treated by Vitamin D and Magnesium --- 1. See also VitaminDWiki Headache category has the following
Metal Migraine No Migraine Ratio
Cadmium 0.36 ug 0.09 ug 4X MORE if decrease
Iron 0.97 ug 0.48 ug 2X MORE if decrease
Lead 1.48 ug 0.78 ug 2X MORE if decrease
Magnesium 10.6 ug 34.5 ug 3.5X LESS if increase
Zinc 0.24 ug 5.77 ug 24X LESS if increase
Pages listed in BOTH the categories Headache and Magnesium {category}

Download the PDF from VitaminDWiki

image

BACKGROUND AND OBJECTIVES:

Vitamin D deficiency and insufficiency are related with many neurological diseases such as migraine. The aim of this study was to investigate whether pediatric migraine is associated with vitamin D deficiency and the effect of vitamin D therapy on the frequency, duration, severity of migraine attacks, and Pediatric Migraine Disability Assessment (PedMIDAS).

MATERIALS AND METHODS:

We retrospectively examined the patients' levels of calcium, phosphorus, parathyroid hormone, alkaline phosphatase, and 25-OH vitamin D of 92 pediatric migraine patients. The patients were divided into two groups: Group 1, which had low vitamin D levels and received vitamin D therapy, and group 2, which had normal vitamin D levels and did not receive vitamin D therapy. Migraine severity measured by the visual analog scale (VAS), migraine frequency, and duration as well as scores on the PedMIDAS questionnaire were compared with regard to the 25-OH vitamin D levels. In addition, pre- and posttreatment pedMIDAS scores, VAS, migraine frequency, and duration were compared with baseline values.

RESULTS:

A total of 34.7% patients had vitamin D insufficiency (vitamin D levels between 10 and 20 ng/mL), whereas 10.8% had vitamin D deficiency (vitamin D levels < 10 ng/mL). Migraine frequency, migraine duration, and PedMIDAS scores were significantly higher in the group 1 than group 2 (p = 0.004, p = 0.008, and p = 0.001). After vitamin D therapy at sixth months of supplementation, migraine duration was reported statistically significant shorter (p < 0.001) and the migraine frequency, VAS scores, and pedMIDAS scores were statistically significant lower compared with baseline values in group 1 (p < 0.001).

CONCLUSION:

We found a marked correlation between pediatric migraine and vitamin D levels. Vitamin D therapy was beneficial in migraine pediatric patients.